By

Alex Harding

27
Jun
2023

Biopharma Has a Primary Care Problem

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
7
Mar
2022

The Globally Integrated Biotech Is Down, But Not Out

“What else can you do? The entire isolation of Russia. Nowadays we see real solidarity of the whole world to cancel or stop any economic, cultural, technological, financial connections with Russia and we urge the same from the Drug Discovery community.” This was the message on Mar. 5 from Andrey Tolmachov, founder and CEO of Enamine Ltd., a Ukrainian chemistry...
Read More
30
Dec
2021

A Doctor’s View From the Front Line of the Omicron Wave

My phone buzzed with alerts about record-setting case numbers as I rushed between patients. A pile of tiny bottles with swabs floating in pink liquid accumulated while awaiting PCR testing. Patients with coughs and sniffles lined up outside the door, waiting to be seen. My shift as an internal medicine physician yesterday in MGH Chelsea’s urgent care facility reminded me...
Read More